Brain imaging research reveals where psychedelic compounds such as psilocybin and LSD manifest their effects.
There is much research into psychedelic treatment of mental disorders, but psychedelics might be effective in treating autoimmune disorders as well.
The monoamine hypothesis of depression leaves many patients without effective help. It’s time for a paradigm shift, and psychedelics may be leading the way.
A default level of brain activity sheds light on the source of consciousness and mechanisms of ego death.
While ketamine produces a whole symphony of effects in the brain, surprisingly, a localized neural oscillation in a lesser-known area of the brain is enough to cause feelings of dissociation.
Research suggests that BDNF can help rewire and overwrite stubborn neural pathways by creating new connections that facilitate more flexible and adaptive thoughts and behaviours. Psychedelics appear to tap into this mechanism.
THC binding to 5-HT2A may activate signaling pathways that cause negative effects on cognition and memory.
"Now we know how psychedelic drugs work – finally! We might be able to switch some effects on while keeping others off."
Stronger binding interactions between MDMB-Fubinaca and CB1 may explain why some synthetic cannabinoids cause dangerous effects.
High-resolution structure reveals how LSD binds to and activates the canonical mind-altering receptor.